Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering is a biopharmaceutical company with a focused approach on improving patient outcomes through their proprietary computational Disease Cancelling Technology platform. The company's strong capabilities in computational biology make them an attractive partner for larger pharmaceutical companies and their drug discovery programs. With the potential for promising results and growth in the future, Immuneering's stock has a positive outlook for investors.

Bears say

Immuneering is currently dependent on its proprietary computational Disease Cancelling Technology platform and partnerships with other pharmaceutical companies for its drug discovery programs, which could be a vulnerability. Additionally, the success of its potential treatments, including its MEK inhibitor, heavily relies on further clinical validation and regulatory approval, making the company's future uncertain. Overall, while Immuneering has potential in the biopharmaceutical industry, the company's success is heavily dependent on the success of its current treatments, and there are significant risks and uncertainties that could impact its future performance.

Immuneering Corp (IMRX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immuneering Corp (IMRX) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.